Fetal Anemia

Fetal anemia

Fetal anemia is a reduction in fetal hemoglobin concentration

Severity:

• Mild: Hb 0.8–1.0 MoM
• Moderate: Hb 0.55–0.8 MoM
• Severe: Hb <0.55 MoM

Clinical relevance starts once anemia is moderate or worse.

Etiologic classification

1. Immune fetal anemia

Caused by maternal IgG antibodies crossing placenta and destroying fetal RBCs.

Common causes:

• Rh(D) alloimmunization
• Other red cell antibodies:
  • Kell (K)
  • c, E
  • Duffy, Kidd

2. Non-immune fetal anemia

A. Increased destruction

• Parvovirus B19
• Hemoglobinopathies
• Enzyme defects
• Microangiopathy

B. Decreased production

• Parvovirus B19 (pure red cell aplasia)
• Bone marrow failure syndromes
• Chromosomal disorders

C. Blood loss

• Fetomaternal hemorrhage
• Twin–twin transfusion
• Placental tumors (chorioangioma)
• Cord accidents

Pathophysiology

Anemia causes:

• ↓ blood viscosity
• ↑ cardiac output
• ↑ cerebral blood flow

Result:

• Increased peak systolic velocity in the MCA

Diagnosis of fetal anemia

1. Ultrasound signs (late, insensitive)

• Hydrops fetalis
• Ascites
• Skin edema
• Cardiomegaly
• Placental thickening

2. MCA-PSV Doppler (cornerstone)

Principle

• MCA-PSV correlates inversely with hemoglobin concentration.

Cutoff

• MCA-PSV ≥ 1.5 MoM → suggests moderate to severe anemia

Sensitivity and specificity

• Sensitivity for moderate–severe anemia: ~85–90%
• Specificity: ~75–80%

Very good for clinically actionable anemia.

Why mild anemia is often missed

This is critical and often underappreciated.

Reasons MCA-PSV misses mild anemia

• Hemodynamic compensation is subtle
• Blood viscosity change is minimal
• Physiologic overlap with normal fetuses
• Measurement variability

So: Mild anemia (Hb 0.8–1.0 MoM) can have normal MCA-PSV

Special situation: Kell alloimmunization

• Suppressed erythropoiesis
• Less hyperdynamic circulation
• MCA-PSV may underestimate severity

Management overview

Immune fetal anemia

Stepwise:

• Maternal antibody titers
• MCA-PSV surveillance
• Cordocentesis when indicated
• Intrauterine transfusion (IUT)

Non-immune fetal anemia

Treat cause when possible:

• Parvovirus → supportive ± IUT
• FMH → transfusion
• TTTS → laser therapy

Role of IVIG in immune fetal anemia

IVIG is used to:

• Reduce transplacental antibody-mediated hemolysis
• Delay onset or progression of fetal anemia

It does not replace IUT once anemia is established.

Indications for IVIG

Most commonly:

• Severe Rh or Kell alloimmunization
• History of:
  • Early fetal demise
  • Hydrops before viability
• High maternal antibody titers early in pregnancy

Used prophylactically, before anemia becomes severe.

Mechanism of action

IVIG:

• Saturates Fc receptors
• Reduces placental antibody transfer
• Modulates maternal immune response

Regimens (typical)

• 1 g/kg weekly, or
• 2 g/kg every 2–3 weeks

Started as early as 12–16 weeks in high-risk cases.

Effectiveness

• Delays need for first IUT
• Reduces severity of anemia
• Improves survival in severe alloimmunization

Age-dependent fetal adaptive response

1. Why fetal–maternal IgG transfer increases with gestation

Placental biology

• IgG transfer occurs via FcRn receptors on syncytiotrophoblast
• FcRn expression and placental surface area increase with gestation
  • Minimal transfer in early 2nd trimester
  • Steep rise after 24–26 weeks
  • Maximal transfer in 3rd trimester

Maternal antibody titers may be stable, but fetal exposure keeps rising.

This is why immune fetal anemia often worsens later, even without a rise in maternal titers.

2. The fetal counter-response: expanding erythroid reserve

The fetus responds on three levels: marrow expansion, extramedullary hematopoiesis, and physiologic adaptation.

3. Erythropoiesis shifts with gestational age

Early gestation

• Liver and spleen dominate erythropoiesis
• Bone marrow contribution is limited
• Low reserve, poor buffering capacity
• Early immune anemia progresses rapidly
• Hydrops can occur with modest antibody exposure

Mid to late gestation: marrow takes over

By ~20–24 weeks:

• Bone marrow becomes the primary erythropoietic organ
• Progressive recruitment of:
  • Long bones
  • Iliac crest
  • Vertebrae
  • Ribs

By the third trimester:

• Iliac crest and long bones are major RBC factories
• Total erythroid mass and turnover capacity increase sharply

4. Expansion of the erythroid base (the key concept)

With rising maternal IgG transfer, the fetus compensates by:

1. Increasing erythropoietin (EPO)

• Produced mainly by fetal liver and kidneys
• Rises exponentially in anemia
• Drives marrow hyperplasia

2. Marrow recruitment and expansion

• Long bones and iliac crests show:
  • Increased erythroid precursors
  • Increased reticulocyte output
• This buffers antibody-mediated hemolysis

Clinically:

• Same antibody titer causes less severe anemia later than earlier

3. Extramedullary hematopoiesis

• Liver and spleen re-expand production
• Leads to:
  • Hepatosplenomegaly
  • Increased cardiac preload

This is compensatory, not pathologic initially.

5. Fetal "behavioral" and physiologic responses to anemia

As anemia increases, the fetus shows predictable responses:

Hemodynamic

• ↑ cardiac output
• ↓ blood viscosity
• ↑ cerebral perfusion (MCA-PSV rise)

Movement and tone

• Early anemia: normal movements
• Moderate anemia: increased activity (hyperdynamic state)
• Severe anemia: ↓ movements (pre-terminal)

6. Fetal anemia may appear "stable" despite rising antibody titers

• Maternal antibody transfer ↑
• Antibody titers stable or rising
• Yet:
  • MCA-PSV remains <1.5 MoM
  • Hydrops absent

The expanding erythroid base and increasing marrow productivity temporarily outpace hemolysis.

This buffering capacity:

• Improves with gestation
• Is much better after 26–28 weeks
• Is why late disease can look deceptively mild

7. Why this compensation eventually fails

Compensation fails when:

• Hemolysis exceeds production
• Or marrow function is impaired

Examples:

• Kell alloimmunization
  • Antibodies suppress erythroid progenitors
  • Erythroid base cannot expand effectively
  • Doppler underestimates severity
• Very high antibody load
• Superimposed infection or hypoxia

8. Clinical implications

1. Timing matters more than titer

• Same titer at 18 weeks ≠ same risk at 32 weeks
• Early disease is more dangerous

2. MCA-PSV reflects physiology, not antibody burden

• Stable Dopplers mean compensation is holding
• Sudden rise means reserve is exhausted

As gestation advances:

• Antibody exposure ↑
• Placental transfer ↑
• Erythroid capacity ↑ even more

Disease severity depends on which curve rises faster.

A. Maternal–fetal IgG transfer

• IgG transfer across the placenta is minimal before 16–18 weeks
• It rises steeply after 24 weeks
• Peaks in the third trimester, often exceeding maternal levels

So paradoxically, the fetus is exposed to more antibody later, not earlier.

B. Fetal erythropoietic capacity increases with gestation

Early gestation:

• Limited erythropoiesis
• Liver-dominant, small marrow volume
• Minimal reserve

Later gestation:

• Expansion of erythroid niches:
  • Bone marrow (long bones, ribs, vertebrae)
  • Iliac crest
• Increased erythropoietin responsiveness
• Faster reticulocyte release
• Ability to mount compensatory erythropoiesis

This is why many fetuses tolerate rising antibody titers for a long time before decompensating.

3. Hemodynamic response to anemia is age-independent

When fetal anemia develops, regardless of gestational age, the fetus shows a stereotyped cardiovascular response:

• Reduced blood oxygen content
• Cerebral vasodilation
• Reduced blood viscosity
• Increased cardiac output
• Increased systolic velocity in cerebral arteries

These responses are qualitatively the same at 18 weeks and at 32 weeks.

Clinical implications

• Rising maternal antibody titers alone do not mandate intervention
• Surveillance should focus on:
  • MCA-PSV trends
  • Not absolute gestational age
• IVIG delays anemia by reducing hemolysis, effectively buying time for erythroid compensation
• MCA Doppler detects the point at which compensation fails